Lafayette Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Lafayette Investments’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17K	Hold	13,000	–	–	﹤0.01%	162
2026 Q1	$20.5K	Hold	13,000	–	–	﹤0.01%	157
2025 Q4	$21.7K	Hold	13,000	–	–	﹤0.01%	156
2025 Q3	$22K	Hold	13,000	–	–	﹤0.01%	155
2025 Q2	$11.8K	Hold	13,000	–	–	﹤0.01%	150
2025 Q1	$5.87K	Hold	13,000	–	–	﹤0.01%	146
2024 Q4	$6.53K	Hold	13,000	–	–	﹤0.01%	149
2024 Q3	$11.8K	Hold	13,000	–	–	﹤0.01%	146
2024 Q2	$13K	Hold	13,000	–	–	﹤0.01%	142
2024 Q1	$19.2K	Hold	13,000	–	–	﹤0.01%	141
2023 Q4	$14.2K	Hold	13,000	–	–	﹤0.01%	135
2023 Q3	$15.3K	Hold	13,000	–	–	﹤0.01%	128
2023 Q2	$18.3K	Hold	13,000	–	–	﹤0.01%	126
2023 Q1	$19.5K	Hold	13,000	–	–	0.01%	124
2022 Q4	$15.2K	Hold	13,000	–	–	﹤0.01%	121
2022 Q3	$15K	Hold	13,000	–	–	﹤0.01%	117
2022 Q2	$21K	Hold	13,000	–	–	0.01%	120
2022 Q1	$20K	Hold	13,000	–	–	0.01%	128
2021 Q4	$32K	Hold	13,000	–	–	0.01%	125
2021 Q3	$33K	Hold	13,000	–	–	0.01%	125
2021 Q2	$37K	Hold	13,000	–	–	0.01%	124
2021 Q1	$31K	Buy	13,000 +3,000	+30%	+$7.2K	0.01%	90
2020 Q4	$18K	Buy	+10,000	New	+$14K	0.01%	87

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Lafayette Investments's LCTX Position: Q2 2026 in Review

Lafayette Investments held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 13,000 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #162.

Lafayette Investments first reported a position in LCTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $37K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Lafayette Investments held 13,000 shares of Lineage Cell Therapeutics worth $17K as of Q2 2026.
Lafayette Investments left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Lafayette Investments's portfolio in Q2 2026, its #162 holding.
Lafayette Investments first reported a position in Lineage Cell Therapeutics in Q4 2020 and has held it in 23 quarters since.
Lafayette Investments's Lineage Cell Therapeutics position peaked at $37K in Q2 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Lafayette Investments's 13F filing for Q2 2026, filed 11 Aug 2026.